Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-29T02:11:11.938Z Has data issue: false hasContentIssue false

Systemic pneumococcal disease in Norway 1995–2001: capsular serotypes and antimicrobial resistance

Published online by Cambridge University Press:  26 February 2004

M. K. PEDERSEN
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
E. A. HØIBY
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
L. O. FRØHOLM
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
V. HASSELTVEDT
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway Present address: Department of Microbiology, Sykehuset Innlandet HF, NO-2629 Lillehammer, Norway.
G. LERMARK
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
D. A. CAUGANT
Affiliation:
Division of Infectious Disease Control, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway Department of Oral Biology, University of Oslo, Oslo, Norway
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A total of 4624 pneumococcal isolates from episodes of systemic pneumococcal disease were received at the Norwegian Institute of Public Health during the period 1995–2001. All isolates were serotyped and tested for susceptibility to benzylpenicillin, lincomycin, erythromycin, tetracycline and trimethroprim–sulphamethoxazole. The proportion of strains resistant to these antimicrobial agents remained stable at a low level, ranging from 0·1% for benzylpenicillin to 2·5% for erythromycin. The distribution of serotypes was also stable over the 7 years: serotypes 1, 4, 9, 14, 7, 6 and 23 were the most frequent, representing 70·5% of isolates. Overall, 95·8% of the isolates were of serotypes/groups included in the current 23-valent polysaccharide vaccine, 52·2% were of serotypes/groups included in the 7-valent conjugated vaccine and 85·5% were of serotypes/groups included in the 11-valent conjugated vaccine.

Type
Research Article
Copyright
© 2003 Cambridge University Press